Fecal pancreatic elastase ELISA kits will lead fecal pancreatic elastase testing sales through 2036 with a 61% share of the product segment in 2026. The market is expected to reach USD 18.8 billion in 2026 and USD 39.2 billion by 2036, creating an absolute opportunity of USD 20.4 billion.